Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

UT Health San Antonio breast oncologists, scientists to present novel research at SABCS 2020


This year’s San Antonio Breast Cancer Symposium (SABCS) will take place virtually from Dec. 8 through Dec. 11. One of the largest breast cancer meetings in the world, the four-day conference was founded and is owned and operated by the Mays Cancer Center, part of The University of Texas Health Science Center at San Antonio.

Members of the media who wish to register or to learn more about the symposium can visit sabcs.org.

This year’s conference will feature an oral presentation by Manjeet Rao, PhD, about a possible FDA-approved anti-depressant being studied that may block breast cancer growth by preventing breast cancer cells from repairing themselves.

Dr. Rao has been studying the unique ability of cancer cells to repair DNA damage caused by either unchecked growth or chemotherapy and radiation. Even though breast cancer cells can’t repair all the damage themselves, they recruit back-up DNA repair systems in the body to help damaged cells survive and continue replicating. These back-up DNA repair systems can cause previous treatments not to work if cancer returns. “Our pre-clinical and clinical data show that a drug that can inhibit the alternate DNA repair pathway signaling may promote immune surveillance, and therefore may serve as a novel treatment option for treating breast cancer patients,” Dr. Rao said.

He will be presenting preliminary results from a clinical trial that is being conducted exclusively at UT Health San Antonio to evaluate the anti-depressant drug Imipramine that may inhibit breast cancer growth by stopping the alternate repair programs. The presentation will be given during the afternoon session on Tuesday, Dec. 8, between 1 and 3 p.m.

Dr. Rao is a professor of cell systems and anatomy, deputy director of the Greehey Children’s Cancer Research Institute based in the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio, and is co-leader of experimental and development therapeutics at the Mays Cancer Center.

Poster sessions

A sampling of the posters offered by UT Health San Antonio faculty members are as follows:

Andrew Brenner, MD, PhD, a medical oncologist and associate professor in the Division of Hematology and Medical Oncology, studies breast cancer, including breast cancer that has spread to the brain. The blood-brain barrier, a specialized rim of cells around the outside of the brain, allows nutrients in but prevents many substances from entering, including many cancer treatments; therefore, it has been difficult to treat brain tumors in the past. Scientists have been studying how to piggyback potent drugs onto specially designed molecules that are capable of entering the brain.

Dr. Brenner’s poster is based on a clinical trial conducted only at the Mays Cancer Center that evaluated the ability of an FDA-approved antibody called sacituzumab govitecan (SG) to carry a highly potent chemotherapy drug, SN-38, to the tumors without injuring healthy tissue.

He tested this theory in two groups of patients: one group of 11 patients with highly aggressive triple-negative breast cancer that had spread to the brain, and a second group of 10 patients with glioblastoma, another form of aggressive cancer that originates in the brain or spinal cord. After receiving an initial dose of SG carrying SN-38, both sets of patients had tumors surgically removed for analysis.

Early results showed that most patients with metastasized breast cancer showed improvement, while all glioblastoma patients still showed some measurable disease. Final results of the trial will be revealed in the poster session.

Patricia Chalela, MPH, DrPH, is an associate professor in UT Health San Antonio’s Institute for Health Promotion Research. She is working on a smartphone app to encourage patients to continue using hormone therapy, which has been proven to contribute to the reduction of recurrence and death from breast cancer long term, as high as a 50% reduction into the second decade after breast cancer diagnosis.

The purpose of her app is to promote continued adherence to hormone therapy among breast cancer patients while increasing patient education, enhancing self-efficacy, facilitating communication with the medical team and helping patients develop self-care skills to promote optimal adherence to hormone therapy.

Virginia Kaklamani, MD, is a professor and leader of the breast cancer program at the Mays Cancer Center, and one of three co-leaders of the SABCS. She has been studying new ways to classify subtypes of triple-negative breast cancer.

“We evaluated the relationship between the tumors’ unique gene expression signatures to the known tumor subtypes using a tumor characterization tool called BluePrint,” she said. The new technology describes the “chain reaction” of chemical processes within the tumor to more specifically characterize the tumor. “These data suggest that molecular classification by BluePrint adds further precision in classifying triple-negative breast cancer in patients and sheds new light on the differences among these tumors,” she said. This information is valuable to cancer physicians in matching the tumor subtype to the most effective treatment.

Kate Lathrop, MD, breast medical oncologist and associate professor of medicine at the Mays Cancer Center, also is studying triple-negative breast cancer. In collaboration with Ausio Pharmaceuticals, she is exploring a new oral medication that targets the cancer’s estrogen beta receptor. This medication, S-equol, was given to women with triple-negative breast cancer for two to three weeks.

“Tumor samples from before and after taking the medication were compared, and on average, the speed of tumor growth was decreased. This is encouraging as there are relatively few treatments for triple-negative breast cancer,” Dr. Lathrop said. The medication was well tolerated and had few side effects. Additional studies are currently being planned for S-equol, she said.

# # #

The Mays Cancer Center, part of The University of Texas Health Science Center at San Antonio, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. Visit cancer.uthscsa.edu.

Share article on social media or email:

MaxQ AI Partners with Fujifilm to Commercialize the ACCIPIO® Suite of Clinical Artificial Intelligence Applications


MaxQ AI

In collaboration with FujiFilm and the wonderful staff at Capital Health Hospital, our teams have successfully integrated Accipio into Fujifilm’s Synapse PACS, achieving a seamless clinical workflow enhanced with deep clinical AI.”

MaxQ AI, the industry-leading healthcare technology company that delivers comprehensive clinical workflow with improved patient triage and diagnosis, announced today a multi-year partnership with FUJIFILM Medical Systems U.S.A., Inc., a leading provider of enterprise imaging solutions, to commercialize the ACCIPIO® Clinical Platform.

The Accipio Clinical Platform generates multiple insights into a patient’s medical imaging study that may provide a faster and clinically accurate diagnosis. The platform is comprised of Accipio Ix (Intracranial Hemorrhage (ICH) triage and notification, Accipio Ax (Slice-Level Annotation), and Accipio Dxg (Triage for ICH Presence or Absence)**. MaxQ is the only AI platform company offering advanced AI applications and AI platform solutions, such as MaxQ Xpress, as a seamless, integrated offering, secured through ISO 27001 and ISO 27799 cybersecurity standards. When launched through Fujifilm’s Synapse PACS platform, which ranks among the fastest and most secure enterprise imaging solutions in the industry—the Accipio and Synapse seamless solution deliver deep clinical and actionable insights, enabling clinicians to make faster assessments of patients.

“At MaxQ, our goal is to equip physicians with AI-based solutions that enable them to deliver faster, more confident patient care, while reducing costs, and physician workload,” says Michael Rosenberg, Chief Executive Officer of MaxQ. “We’ve worked extensively with Fujifilm over the last year on our deployment at Capital Health Hospitals in New Jersey. In collaboration with Fujifilm and the wonderful staff at Capital Health Hospital, our teams have successfully integrated Accipio into Fujifilm’s Synapse PACS, achieving a seamless clinical workflow enhanced with deep clinical AI.”

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It’s ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm’s in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit http://www.fujifilmhealthcare.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $22.1 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: http://www.fujifilmholdings.com.

About MaxQ AI, Ltd.

MaxQ AI is transforming healthcare by empowering physicians to provide ‘smarter care’ with enhanced clinical workflow, improved patient triage and artificial intelligence (AI) clinical insights. Based in Tel Aviv, Israel and Andover, MA our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing intracranial hemorrhage, stroke, brain trauma, and other serious conditions. To learn more, visit http://www.maxq.ai or follow us on LinkedIn.

Press Contacts:

For MaxQ AI:

marketing@maxq.ai

For Fujifilm:

Danielle Brown, Danielle.brown@fujifilm.com

**MaxQ Device Regulatory Status Available at http://www.maxq.ai

Share article on social media or email:

American College of Medical Toxicology COVID-19 ToxIC Sub-Registry


Toxicology Investigators Consortium

“ACMT is very honored to receive this contract from FDA for this important project related to medication safety surveillance,” said Dr. Paul M. Wax, ACMT’s Executive Director and co-founder of ToxIC.

ACMT’s Toxicology Investigators Consortium (ToxIC) is a unique multicenter toxicosurveillance and research network comprised of physicians specifically qualified in the field of medical toxicology. Since the network’s establishment in 2010, there have been over 73,000 cases recorded into ToxIC’s Patient Registry from 40 participating sites across the United States comprised of more than 60 hospitals and clinics. ToxIC was designed to provide accurate, reliable and timely data on adverse effects arising from exposures to medications, drugs of abuse, natural substances, metals, pesticides, or other chemical substances.

The COVID-19 Sub-Registry will be developed as an enhanced data collection tool within the ToxIC network that will specifically focus on identifying potential adverse reactions related to COVID-19 drug treatments. Physicians specialized in medical toxicology will oversee the program at 15 designated medical centers across various geographic regions in the United States.

“ACMT is very honored to receive this contract from FDA for this important project related to medication safety surveillance,” said Dr. Paul M. Wax, ACMT’s Executive Director and co-founder of ToxIC. “For over a decade, ACMT has worked diligently to develop the ToxIC Program as a useful tool for adverse drug reactions and overdose surveillance.” Jeffrey Brent, MD, PhD, Co-Principal Investigator on this project states that “particularly now, in the midst of the COVID-19 pandemic, we anticipate this collaboration will deliver critical data that could improve public health decision making.”

The FDA has had a contract with ACMT to access the ToxIC Registry for three years. The new ToxIC Sub-Registry is designed to provide FDA’s Center for Drug Evaluation and Research (CDER) safety data related to drug therapies used in patients with or suspected to have COVID-19. ACMT will work in close collaboration with scientists in CDER’s Office of Surveillance and Epidemiology (OSE) and Office of Translational Sciences (OTS).

The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology. Our members specialize in the prevention, evaluation, treatment, and monitoring of injury and illness from exposures to drugs and chemicals, as well as biological and radiological agents. ACMT members work in clinical, academic, governmental, and public health settings, and provide poison control center leadership.

Share article on social media or email:

KYOCERA and MUTUALINK Help First Responders Save Precious Time Communicating in Emergencies


Kyocera DuraForce PRO 2 ultra-rugged smartphone with Mutualink Edge@Team multimedia PTT helps first responders save precious time in emergencies.

This solution turns the ultra-rugged DuraForce PRO 2 into a mobile Command Center with real-time communication along with highly secure video, location and data sharing to streamline operations when it counts the most.

Time is never more precious than in an emergency. The right communication tool can literally save lives. With the advanced Mutualink @Team multimedia push-to-talk (PTT) application and Kyocera’s ultra-rugged DuraForce PRO 2 Android™ smartphone, first responders can reduce crucial communication time with quick access to individuals and information. The secure multimedia PTT with broadband connectivity provides Incident Command System (ICS) based True Interoperability® between agencies in emergencies, enabling instant real-time sharing of crucial video, text messages and location to pre-determined or ad hoc talkgroups. The @Team app is an easy download from the Google Play™ store on DuraForce PRO 2*.

First responders can find themselves in extreme temperatures and weather – fires, snowstorms, flashfloods, etc. – and they require a mobile device that can withstand the elements. Kyocera’s DuraForce PRO 2 is built rugged from the inside out, without bulk, with cutting-edge technology and features designed to function seamlessly in life’s emergencies. Its built-in certified IP68 dust proof and waterproof and Military Standard 810G protection against drops, shock, dirt, rain, snow, and other harsh conditions ensure the device can withstand even the harshest environments. Robust all-day batteries easily power through shifts and front-facing dual loudspeakers with an advanced echo and noise cancellation system enable clear audio even in the noisiest situations. A dedicated button can be programmed for instant one-touch communication using the @Team PTT app. A wide-angle lens captures images and video in both vertical and horizontal formats, enabling first responders to share more accurate images of their environments, providing a cost-effective body worn camera option. The touchscreen is designed to work when wet or with gloves, ensuring ease-of-use in emergency situations. Android Enterprise Recommended with ongoing security updates, the device utilizes FIPS 140-2 validation module and includes a fingerprint security sensor for biometric authentication, plus it’s covered by a 2-year manufacturer’s warranty that includes water damage.

“Fast, accurate communication is important for every industry, but never as much as when getting crucial information during an emergency since lives can depend on it,” said Vipul Dalal, general manager at Kyocera’s Communications Equipment Group. “Hardware, software and network capabilities must be optimized at all times for first responders to communicate instantly with each other and other agencies. This solution turns the ultra-rugged DuraForce PRO 2 into a mobile Command Center with real-time communication along with highly secure video, location and data sharing to streamline operations when it counts the most.”

“Pairing Mutualink’s multimedia interoperability apps with Kyocera’s ultra-rugged smartphones creates more competitive choice for the nation’s first responders, who require dependable, flexible communications solutions to more quickly resolve emergency incidents,” said Joe Mazzarella, president and chief operating officer of Mutualink. “This partnership with Kyocera is our next step in providing extended communications solutions during the coronavirus pandemic, enabling clear, complete and timely sharing of information between and among first responders, hospitals and private security teams.”

Kyocera’s rugged devices are used by first responders nationwide and Mutualink has been providing secure, interoperable communications to public safety for years, making the combined offering an especially trusted, reliable solution. The @Team application on DuraForce PRO 2 enables:

Push-to-Talk Plus Video – secure push-to-talk. Beyond traditional voice PTT, emergency teams can share photos, locations, streaming video, even data files with each other.

One-to-Many Sharing – secure one-to-many voice, text, video and data sharing to a group in real time. Each user can also participate in collaboration sessions with outside agencies through their agency’s Interoperable Workstation (IWS) appliance or Edge IWS application.

EoIP & Location Services – secure Everything-over-IP protocol turns push- to-talk to push-to-see + talk. All forms of connectivity are supported. Geolocation maps show where your team is in real time (optional by device/user).

Multiple Talkgroups – multiple talkgroups are possible per device, including managed and ad hoc groups. Broadcast voice, video and text to all group members at once.

Access to the Mutualink Network – users can participate in network incidents to collaborate daily with other agencies for large planned events and during emergency situations. Mutual aid incidents resolve faster with LMR – LTE communications bridged across agencies.

Secure & Scalable

The secure and scalable @Team is HIPAA- and FERPA-compliant, with AES-256 encryption to protect communications from leakage or hacking plus a Virtual Private Network (VPN) for added security.

DuraForce PRO 2 and Mutualink are certified to operate on FirstNet — built with AT&T — the first nationwide network dedicated to public safety, and the Verizon network.


  • Mutualink app is a separate download and purchase.


**IP68 dust proof and waterproof for water immersion up to 6.5 feet for up to 30 minutes.

ABOUT KYOCERA

Kyocera International Inc.’s Communications Equipment Group (CEG) is the headquarters for Kyocera wireless devices in the Americas. With a history of quality and innovation delivering many “firsts” to the U.S. market, Kyocera is the leader in rugged mobile solutions. Launching more than 100 waterproof and rugged mobile devices globally over the last 10+ years, Kyocera strives to offer rugged, reliable technology as an integral part of a total mobile offering: combining Military Standard 810G-certified ruggedization and enterprise-grade security with a partner ecosystem, industry-specific applications and innovative accessories. Working with leading service providers, Kyocera has created a “Total Solution” offering that helps deliver a significantly lower total cost of ownership to a wide range of industries such as public safety, transportation, and construction. White glove services including overnight advanced replacement, custom provisioning, repair, and more help productivity for business customers. When it comes to blending performance, durability and support, Kyocera’s rugged mobile solutions are in a class of their own. For more information, visit Kyoceramobile.com or follow the company on Facebook, Twitter, Youtube, Instagram and LinkedIn.

Kyocera Corporation (TOKYO: 6971), the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as “advanced ceramics”). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2020, the company’s consolidated sales revenue totaled 1.6 trillion yen (approx. US$14.7 billion). Kyocera is ranked #549 on Forbes magazine’s 2020 “Global 2000” list of the world’s largest publicly traded companies.

About Mutualink

Mutualink, Inc. provides an interoperable communications platform that enables community-wide multimedia sharing of radio, voice, text, video, data files, and telephone communications in a secure environment. Mutualink’s system is deployed by thousands of public safety and private security entities and facilities, including homeland security, police and fire departments, emergency operations centers, hospitals, schools and universities, transit authorities, stadiums, shopping malls, casinos, and more. Mutualink is a privately held company headquartered in Wallingford, CT, with R&D facilities in Westford, MA; Allen, TX; and Mayagüez, PR. For more information, please visit http://www.mutualink.net.

True Interoperability® is a registered trademark of Mutualink, Inc.

© 2020 KYOCERA International, Inc. (KII), San Diego, California, USA. All rights reserved. No reproduction in whole or in part is allowed without prior written approval. Kyocera is a registered trademark of Kyocera Corporation. DuraForce PRO 2 is a trademark of Kyocera International, Inc. Google and Android are trademarks of Google LLC. All other marks are held by their respective owners.



A Christmas Like No Other– Despite Many Obstacles, Christmas Tree Sales Are Robust


News Image

“In this very unusual year, Christmas trees of all kinds, sizes, shapes, colors and price, real and artificial, are taking on greater significance.”

Sales of Christmas trees, both real and artificial, are surging this season, despite being the most challenging year for both business and consumers in modern times.

“Many of our members have seen sales increases of 200 percent over the same time last year,” said Jami Warner, Executive Director of the American Christmas Tree Association (ACTA). “We are very grateful to be in the business of bringing some much-needed joy to so many facing unforeseen hardships,” Warner added.

Early holiday decorating gave the Christmas season a jump-start, with strong Christmas tree sales beginning at the end of summer, said Warner.

“With many experts encouraging an early start to holiday decorating to help boost morale and mental health, Christmas trees became an even hotter commodity,” Warner said.

“Christmas trees have always been the traditional centerpiece of the holiday season. And in this very unusual year, Christmas trees of all kinds, sizes, shapes, colors and price, real and artificial, are taking on greater significance,” she added.

Share article on social media or email:

MÜV™ Medical Cannabis Dispensary to Open in Prime Key West Location on Duval Street


News Image

Being in such a high traffic destination, this newest location is a great fit for us. We’re excited about becoming part of the Key West community and building lasting relationships with our patients there

AltMed Florida, one of the fastest growing medical cannabis companies in Florida, continues its statewide expansion with a three-day opening in Key West starting Saturday December 5, 2020 at 10am (pending final approvals) for its newest MÜV™ Medical Cannabis Dispensary.

Location: 519 Duval Street, the most popular street in Key West.

“Having MÜV on iconic Duval Street is a feather in our cap. Residents and visitors will now have access to our award-winning products and top-notch service,” said John Tipton, AltMed Florida CEO. “Being in such a high traffic destination, this newest location is a great fit for us. We’re excited about becoming part of the Key West community and building lasting relationships with our patients there.”

With millions of visitors each year, Duval Street is lined with retail shops, restaurants and nightlife hotspots like Sloppy Joe’s Bar, which is a designated National Historic Landmark. Running north to south from the Gulf of Mexico to the Atlantic Ocean, Duval Street is the epicenter of Key West’s famous party atmosphere.

The Key West MÜV is the southernmost dispensary in the continental U.S. – just around the corner from the famous Mile-0 marker and near the Southernmost Point Buoy, both bustling tourist landmarks. MÜV is also located on the same block as the popular Margaritaville Key West Restaurant.

During the opening, staggered over three-days (Dec.5-Dec.7) for crowd mitigation, all licensed Florida medical cannabis patients will receive a one-time use only, one per patient, 25 percent off their entire first purchase. Patients can order online for express pickup at muvfl.com where they will see real-time live inventory including specific strains and potencies of products.

Deemed an essential service during the pandemic, AltMed Florida has been able to expand its workforce to over 700 employees with additional teams coming onboard at each of its 17 new dispensaries this year. With higher demand for products from 28 total dispensaries, AltMed has also generated additional construction employment and staffing with the expansion of its 220,000-square-foot cultivation facility in Apollo Beach.

The newest state-of-the-art MÜV dispensary will offer an extensive selection of award-winning products including flower, pre-rolls, a wide range of vaporizer pens, metered dose inhalers, topicals, oral sprays, patent-pending encapsulation formulations in its tinctures, 72-hour transdermal patches and transdermal gels. MÜV also has one of the widest selections of concentrates for patients needing macro-dosing options.

Like AltMed Florida’s 27 other locations (Apollo Beach, Bradenton, Bonita Springs, Cape Coral, Clearwater, Deerfield Beach, Fort Myers, Gainesville, Jacksonville/San Marco, Jacksonville Beach, Lady Lake, Lakeland, Longwood/Orlando, Lutz, North Port, downtown Orlando, Ormond Beach, Pensacola, Port St. Lucie, Sebastian, Sarasota, St. Petersburg, Shalimar, Tallahassee, Tampa, Wellington and West Palm Beach) MÜV Dispensaries are designed to provide a premium experience – think Apple Store, with a modern design and expert staff that undergoes extensive training.

The MÜV brand already has a wide following in other legal medical cannabis markets, including Arizona, where it has won five Best of Arizona medical cannabis awards. MÜV products are sold exclusively in Florida at MÜV dispensaries because, unlike other states, Florida does not allow wholesale of product between license holders – only products that license holders make themselves can be sold in their dispensaries.

For more information about the new ADA-compliant MÜV Medical Cannabis Dispensary at 519 Duval Street in Key West, including hours and available MÜV products, visit muvfl.com.

AltMed Florida is on pace to open 40 MÜV Medical Cannabis Dispensaries across the state, all supplied by its 220,000-square-foot, state-of-the-art cultivation facility. Visit this link for images of AltMed Florida’s cultivation operations and watch this brief video to see what makes AltMed Florida and its MÜV™ Medical Cannabis Dispensaries stand out.

About MÜV™ – The MÜV™ brand of medical cannabis infused products launched in Arizona in 2016 and quickly gained international attention and recognition. MÜV Dispensaries by AltMed Florida was formed a year later through the partnership of AltMed Enterprises and Plants of Ruskin, a multi-generational Florida agricultural leader. Through continual research and development, MÜV has received multiple patents for its award-winning MÜV Products line that provides quality, consistent and reliable medical cannabis products to patients at all 29 locations (one in Arizona muv-az.com, 28 in Florida muvfl.com, and more added each month). Patients are encouraged to place reservations online at muvfl.com for in-store pickup, order for delivery, or visit any one of the MÜV Dispensaries for alternative medical cannabis medicine you can trust.

About Plants of Ruskin, LLC – d.b.a. AltMed Florida, LLC – With a focus on quality and attention to detail, Plants of Ruskin has more than 35 years of experience in providing seedlings to farmers for vegetable and medical product production. Plants of Ruskin founders, the Dickman Family, are 4th generation farmers with a long history of working in conjunction with the University of Florida, including an endowed chair specifically dedicated to plant improvement.

About AltMed Enterprises – Alternative Medical Enterprises, LLC, headquartered in Sarasota, FL and doing business as AltMed Enterprises, is a fully integrated medical cannabis company that brings compassion, community engagement and pharmaceutical industry precision to the development, production and dispensing of medical cannabinoids.

Forward-Looking Statements – To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking in nature and merely express our beliefs, expectations or opinions. For example, words such as “may,” “should,” “estimates,” “predicts,” “continues,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” “strategy” and similar expressions are intended to identify forward-looking statements. Such statements are based on current expectations or estimates and involve a number of known and unknown risks and uncertainties that could cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, the following: (i) our ability to implement our business strategy of distributing high quality cannabis products where permissible under applicable law; (ii) availability and cost of additional capital; (iii) our ability to attract, retain and motivate qualified employees and management; (iv) the impact of federal, state or local government regulations; (v) competition in the cannabis industry; (vi) our ability to generate revenues; and (vii) litigation in connection with our business. All forward-looking statements included in this press release and attributable to us or any person acting on our behalf are qualified by this cautionary statement. Forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.

Touchpoint Releases A Powerful New Seat Ticketing Tool to its Church Management System (ChMS), Easing Event Planning For Churches While Saving Money


An auditorium seating schematic with seats highlighted in yellow, red, and blue.

TouchPoint’s Ticketing feature includes the ability to set social distancing rules that automatically trigger as people reserve their chosen seats.

“TouchPoint Ticketing worked flawlessly, and people loved it. Much more efficient use of our space too, which is critical right now. Big win.”

TouchPoint, a church management system (ChMS) used by congregations nationwide, now includes a feature for ticketing individual seats that will help houses of worship plan events and responsibly reopen while maximizing available space.

An engaged community of fans and users of the ChMS regularly suggest new additions or features to the platform, making it purpose-built for the very audience it serves. This latest change is no different. Commissioned by Bellevue Baptist Church in Tennessee, the ticketing feature folds directly into both the desktop and mobile versions of TouchPoint. The integration means churches no longer need to migrate data from third-party vendors like Eventbrite or Brushfire to their church management systems, saving both time and effort.

The new feature also reduces costs. Churches can save over 75% vs. what competitors charge, with even greater cost savings for buying in bulk. According to MarketWatch, these savings will be a welcome boon to congregations, many of which have seen their budgets shrink during the pandemic.

So, while local and statewide closures start and stop until a majority of the public can be vaccinated, TouchPoint users can enjoy the platform’s ticketing feature, which includes customizable social distancing rules that churches can use to maximize their facilities while keeping congregants safe.

Village Bible Church in Illinois especially appreciates the ability to apply social distancing parameters when using the TouchPoint ticketing feature. “It worked flawlessly, and people loved it,” says executive pastor Keith Duff. “Much more efficient use of our space too, which is critical right now. Big win.”

The feature has added functionalities that churches applaud. Unlike other event management and ticketing systems, TouchPoint allows users to build their own venues within the platform while giving churches the flexibility to offer a hybrid of in-person and virtual ticketing. In addition, churches can provide discount codes and services such as childcare during the same ticket-sales process.

“We’re proud to debut a feature that meets a demonstrated need identified by our community of church leaders,” says Andrew Triplett, director of consulting at TouchPoint. “These partnerships guide the platform’s development and ensure its offerings are aligned with what churches truly require, not just what technologists think they need.”

To schedule a demo of the TouchPoint platform and its robust ticketing feature, please email brian.bishop@touchpointsoftware.com.

About TouchPoint

TouchPoint is a powerful, cloud-based church management system that equips leaders to grow fully devoted followers of Christ. TouchPoint is designed for midsize to large churches looking for a ChMS solution that’s ready to use and customizable. Its best-in-class, fully integrated mobile app helps users with contact records, membership management, volunteer management, child check-in, discipleship groups, ministry engagement, contributions, events, media, and more.

Share article on social media or email:

RPhAlly, a Mobile App Exclusively for Pharmacists, Launches the Prescriber Review


Community pharmacists can now provide their professional opinion of a prescriber in the form of a four-star review.

RPhAlly, the new network for pharmacists, today announced the launch of the Prescriber Review, a new tool for community pharmacists. The Prescriber Review is a new feature within the RPhAlly app where pharmacists can provide their professional opinion of a prescriber in the form of a four-star review. When other pharmacists receive prescriptions issued by providers unknown to them, they can utilize the Prescriber Review to see how their colleagues feel about the particular provider.

Pharmacists act as gatekeepers for dispensing controlled substances. They have a corresponding responsibility to make sure the prescription is legitimately prescribed for a valid medical purpose in the usual course of the provider’s professional practice. While pharmacists play a crucial role in combatting the opioid epidemic, many dispense controlled substance prescriptions without knowing the prescriber or their prescribing habits. This innovative tool allows pharmacists to work together to better understand their colleagues’ professional opinions of providers unknown to them and protect their licenses.

“We created this tool so that pharmacists could have an additional data point to serve their patients better and make more informed decisions when dispensing a controlled substance.” – Shawn Bjorndal, RPhAlly Founder.

RPhAlly is committed to becoming a hub for all things pharmacy. The app is free and includes a live feed, a pharmacy specific news feed, pharmacist groups, a directory, and forums. Members can also listen to the Pharmacy Podcast Network from within the platform, the first of many partnerships to come. The Prescriber Review is located within the RPhAlly app, available on Apple and Google Play stores.

About RPhAlly:

RPhAlly is an exclusive platform for pharmacy professionals in the United States to share vital industry information, network with colleagues, grow their careers, and adapt to a rapidly changing industry resulting in more productive, successful, connected, and compliant professionals.

Launched in 2020, RPhAlly allows pharmacists to connect, share, learn, and advocate for the practice of pharmacy all within one app. The platform is available on both iOS and Android or visit https://rphally.com.

Share article on social media or email:

Dr. David Mahjoubi of Ketamine Healing Clinic Los Angeles Featured in Business Insider Article


News Image

I hope this article helps people further understand the remarkable benefits that ketamine IV infusion therapy can have in treating depression symptoms as well as anxiety and chronic pain, says Dr. David Mahjoubi of Ketamine Healing Clinic of Los Angeles.

Dr. David Mahjoubi is among a select group of physicians in the United States to use ketamine as a treatment for depression, anxiety, PTSD and chronic pain. In the informative Business Insider piece, Dr. Mahjoubi details ketamine’s value in improving mental health conditions, such as depression and PTSD, and what a patient can expect when going through the treatment process. He explains how after working at surgical centers throughout Southern California, he quickly noted the beneficial mental effects of IV ketamine in many patients post-procedurally. As a result of this realization, he founded Ketamine Healing Clinic of Los Angeles. The article goes into depth regarding the protocol for ketamine IV treatment at Dr. Mahjoubi’s clinic and the benefits that can lead to the alleviation of depression, including meaningful realizations, decreased anxiety and negative thinking, increased energy and the processing of past trauma. Patients who are not tolerating anti-depressants or are resistant to other forms of treatment often make ideal candidates for ketamine therapy. As a non-opioid and non-addictive treatment, ketamine has also shown valued efficacy for helping chronic pain and fibromyalgia. Dr. Mahjoubi is one of a handful of doctors in the country offering ketamine nasal spray as a supplementary, at-home treatment to help maintain and extend the benefits of IV ketamine treatments.

“I hope this article helps people further understand the remarkable benefits that ketamine IV infusion therapy can have in treating depression symptoms as well as anxiety and chronic pain,” says Dr. David Mahjoubi of Ketamine Healing Clinic of Los Angeles.

Link to Article: https://www.businessinsider.com/anesthesiologist-in-la-who-runs-ketamine-infusion-clinic-2020-11

More About Dr. David Mahjoubi of Ketamine Healing Clinic of Los Angeles:

David Mahjoubi, M.D., is a Diplomate of the American Board of Anesthesiology. He earned his medical degree at The Chicago Medical School and carries over a decade of experience with intravenous ketamine, beginning from his residency training at the University of Southern California (USC) + Los Angeles County Medical Center. Following his residency, Dr. Mahjoubi joined the Anesthesia Group at Northridge Hospital Medical Center and became the most active user of IV ketamine for both conscious sedation and general anesthesia cases. He then founded Ketamine Healing Clinic of Los Angeles, providing a highly effective option for patients with treatment-resistant depression and chronic pain. He is the author of multiple publications in the medical field.

Ketamine Healing Clinic of Los Angeles is located at 1762 Westwood Boulevard, Suite 320. To learn more about Dr. Mahjoubi and the Ketamine Healing Clinic of Los Angeles, please visit http://www.ketaminehealing.com or contact the clinic at (424) 278-4241 or (866) 987-7874.

Share article on social media or email:

NuQuest Appoints Barbara Fairchild to Role of Chief Executive Officer


“Barbara’s extensive expertise in the marketplace will help NuQuest strengthen our partnerships, grow our sales, and take NuQuest to new heights.”

NuQuest, the leading provider of Medicare Secondary Payer (MSP) compliance solutions, including Medicare Set-Aside Allocation (MSA), Medical Cost Projection, and Professional Administration services, is pleased to announce the confirmation of Barbara Fairchild as Chief Executive Officer. Under Ms. Fairchild’s leadership, we look forward to a vibrant and flourishing future for our organization and for the customers that we serve each year.

Ms. Fairchild brings over 35 years of in-depth experience and outstanding performance in the insurance industry specializing in catastrophic case management, drug and medical utilization review, and critical care nursing. This year she was honored as National Programs and Services Division Office MVP for her outstanding contribution to NuQuest and our customers.

Ms. Fairchild holds a bachelor’s degree in nursing from St. Louis University, graduating with honors. Additional professional credentials include Registered Nurse, Certified Life Care Planner, and Medicare Set-Aside Consultant Certified. A sought-after speaker, Ms. Fairchild is nationally recognized as a thought leader and industry expert in Medicare Set-Asides in both worker’s compensation and liability cases. She presents leading-edge, mission-critical information to her diverse audiences in easy-to-understand terms.

“Barbara is the right leader for NuQuest,” said Julie Turpin, Chief People Officer of Brown & Brown, Inc. “Her extensive expertise in the marketplace will help NuQuest strengthen our partnerships, grow our sales, and take NuQuest to new heights.”

About NuQuest

NuQuest is a national provider dedicated solely to Medicare Secondary Payer (MSP) Compliance services, including a complete suite of services for Medicare Set-Aside Allocations (MSA).

With our years of MSP Compliance experience, gained from completing tens of thousands of MSAs and related reports, we work to help our customers realize the maximum cost savings possible in pharmacy utilization and medical treatment.

Our focus on quality, customer service, and technology is key to our success and yours. We employ an experienced and highly credentialed team for the completion of all services; principled customer focus is at the core of our culture. We encourage you to contact us or explore our website to learn more about our team, quality assurance program, and services.

http://www.mynuquest.com

https://www.linkedin.com/company/nuquest-bridge-pointe

866-858-7161

About Brown & Brown, Inc.

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm, providing risk management solutions to individuals and businesses. With more than 80 years of proven success and thousands of teammates, we offer knowledge you can trust and strive to deliver superior customer service. For more information, please visit http://www.bbinsurance.com.

Share article on social media or email: